You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
Attention Score in Context
| Title |
New drugs for migraine
|
|---|---|
| Published in |
The Journal of Headache and Pain, October 2009
|
| DOI | 10.1007/s10194-009-0156-9 |
| Pubmed ID | |
| Authors |
Lars Jacob Stovner, Erling Tronvik, Knut Hagen |
| Abstract |
After the triptans, a calcitonin gene-related peptide blocker (telcagepant) is the first acute medicine that has been developed primarily for treatment of acute migraine. Otherwise, the new drugs have been developed first for other purposes, like anticonvulsants, antihypertensives and antidepressants used for migraine prophylaxis. For acute attacks, a new way to administer a traditional drug like dihydroergotamine is under way, and documentation of efficacy in migraine has been gained for some commonly used painkillers and anti-inflammatory drugs, and for some herbal extracts. Based on insights into the basic pathophysiological mechanisms of the disorder, some drugs have been developed which seem promising in early phase II studies (NOS inhibitors and 5HT1F-receptor agonists). In the future, development and enhancements of existing medicines must be accompanied by increased efforts to develop truly new migraine drugs based on knowledge of the pathophysiology if one wishes to reduce substantially the great burden migraine poses on patients and society. |
Mendeley readers
The data shown below were compiled from readership statistics for 72 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Sweden | 1 | 1% |
| Denmark | 1 | 1% |
| Brazil | 1 | 1% |
| Unknown | 69 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 12 | 17% |
| Researcher | 10 | 14% |
| Student > Ph. D. Student | 8 | 11% |
| Student > Master | 8 | 11% |
| Other | 7 | 10% |
| Other | 16 | 22% |
| Unknown | 11 | 15% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 33 | 46% |
| Pharmacology, Toxicology and Pharmaceutical Science | 7 | 10% |
| Agricultural and Biological Sciences | 5 | 7% |
| Neuroscience | 3 | 4% |
| Chemistry | 2 | 3% |
| Other | 9 | 13% |
| Unknown | 13 | 18% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 May 2023.
All research outputs
#7,866,480
of 23,849,058 outputs
Outputs from The Journal of Headache and Pain
#708
of 1,417 outputs
Outputs of similar age
#34,320
of 95,690 outputs
Outputs of similar age from The Journal of Headache and Pain
#2
of 9 outputs
Altmetric has tracked 23,849,058 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,417 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 17.6. This one is in the 42nd percentile – i.e., 42% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 95,690 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 20th percentile – i.e., 20% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 9 others from the same source and published within six weeks on either side of this one. This one has scored higher than 7 of them.